Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

Vaccine

Volumn 23, Issue 31, 2005, Pages 4011-4015

  Kran, Anne Marte B ^a   Sommerfelt, Maja A ^b   Sørensen, Birger ^b   Nyhus, Jørgen ^b   Baksaas, Ingebjørg ^c   Bruun, Johan N ^a   Kvale, Dag ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Bionor Immuno AS   (Norway)

^c Mericon   (Norway)

Author keywords

Delayed type hypersensitivity; HIV; Immunotherapy

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VACC 4X; VIRUS RNA;

ACTIVE IMMUNIZATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; RNA, VIRAL; VIRAL LOAD;

EID: 20444370204     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.03.010     Document Type: Article

References (18)

1. D.C. Douek, L.J. Picker, and R.A. Koup T cell dynamics in HIV-1 infection Annu Rev Immunol 21 2003 265 304
2. S.A. Calarota, and D.B. Weiner Present status of human HIV vaccine development AIDS 17 Suppl. 4 2003 S73 S84
3. G. Pantaleo, and R.A. Koup Correlates of immune protection in HIV-1 infection: what we know, what we do not know, what we should know Nat Med 10 2004 806 810
4. J.A. Berzofsky, J.D. Ahlers, J. Janik, J. Morris, S. Oh, and M. Terabe Progress on new vaccine strategies against chronic viral infections J Clin Invest 114 2004 450 462
5. M.A. Egan Current prospects for the development of a therapeutic vaccine for the treatment of HIV type 1 infection AIDS Res Hum Retrovir 20 2004 794 806
6. W. Lu, L.C. Arraes, W.T. Ferreira, and J.M. Andrieu Therapeutic dendritic-cell vaccine for chronic HIV-1 infection Nat Med 10 2004 1359 1365
7. A.M. Kran, B. Sorensen, J. Nyhus, M.A. Sommerfelt, I. Baksaas, J.N. Bruun, and D. Kvale HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x) AIDS 18 2004 1875 1883
8. B. Asjo, H. Stavang, B. Sorensen, I. Baksaas, J. Nyhus, and N. Langeland Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy AIDS Res Hum Retroviruses 18 2002 1357 1365
9. R. Angulo, and D.A. Fulcher Measurement of Candida-specific blastogenesis: comparison of carboxyfluorescein succimidyl ester labelling of T cells, thymidine incorporation, and CD69 expression Cytometry 34 1998 143 151
10. C.G. Lange, Z. Xu, B.K. Patterson, K. Medvik, B. Harnisch, and R. Asaad Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function AIDS 18 2004 605 613
11. L. Ruiz, J. Martinez-Picado, J. Romeu, R. Paredes, M.K. Zayat, and S. Marfil Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression AIDS 14 2000 397 403
12. D. Kvale, A.M. Kran, M.A. Sommerfelt, J. Nyhus, I. Baksaas, and J.N. Bruun Divergent in vitro and in vivo correlates of HIV-specific T cell responses during onset of HIV viremia AIDS 19 2005 563 567
13. C.L. Day, and B.D. Walker Progress in defining CD4 helper cell responses in chronic viral infections J Exp Med 198 2003 1773 1777
14. S.A. Migueles, A.C. Laborico, W.L. Shupert, M.S. Sabbaghian, R. Rabin, and C.W. Hallahan HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in non-progressors Nature Imm 3 2002 1061 1068
15. A. Oxenius, D.A. Price, H.F. Gunthard, S.J. Dawson, C. Fagard, and L. Perrin Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection Proc Natl Acad Sci USA 99 2002 13747 13752
16. A.C. Bostrom, B. Hejdeman, R. Matsuda, M. Fredriksson, E.L. Fredriksson, and G. Bratt Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV) Vaccine 22 2004 1683 1691
17. P.A. Haslett, D.F. Nixon, Z. Shen, M. Larsson, W.I. Cox, and R. Manandhar Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy J Infect Dis 181 2000 1264 1272
18. H. Hatano, S. Vogel, C. Yoder, J.A. Metcalf, R. Dewar, and R.T. Davey Jr. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression AIDS 14 2000 1357 1363